(Q48186695)

English

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

Antonio Bertolotto

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Zivadinov R

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Locatelli L

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Cookfair D

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Srinivasaraghavan B

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Ukmar M

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Bratina A

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Maggiore C

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Bosco A

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Grop A

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Catalan M

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Zorzon M

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

9 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

490-501

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Role of MRI in multiple sclerosis I: inflammation and lesions

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Role of MRI in multiple sclerosis II: brain and spinal cord atrophy

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

The measurement and clinical relevance of brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Thalamic Involvement in Multiple Sclerosis: A Diffusion‐Weighted Magnetic Resonance Imaging Study

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Gray Matter Involvement in Multiple Sclerosis: A New Window into Pathogenesis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Focal thinning of the cerebral cortex in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Evidence for progressive gray matter loss in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Voxel-based morphometry–the methods

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Frontal parenchymal atrophy measures in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Relating neocortical pathology to disability progression in multiple sclerosis using MRI

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070446

21 January 2018

Identifiers

10.1177/1352458506070446

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17463072%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48186695&oldid=1086537364"